AVLN
Q3 2026 EPS Estimate
$-0.58
Sep 2, 2026

No analyst ratings available

Price Target Expectations

Bear
$51.00
+69.0%
Consensus
$52.50
+74.0%
Bull
$80.00
+165.2%
12-Month Target Range0 analysts
$51.00$52.50$80.00
Current $30.17Consensus
Current Price
$30.17
Upside to Consensus
$22.33

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev
EPS
FY2028
Rev
EPS
FY2029
Rev
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg
Low
High
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-113M$-97M$-147M$-154M$-156M
Low$-113M$-97M$-172M$-154M$-156M
High$-113M$-97M$-73M$-154M$-156M
EPS Avg$-2.70$-2.31$-2.82$-3.67$-3.74
Low$-2.70$-2.31$-4.12$-3.67$-3.74
High$-2.70$-2.31$-1.74$-3.67$-3.74
Analysts (Rev / EPS) / 1 / 2 / 3 / 1 / 1
Quarterly
MetricQ3 2026Q4 2026
Revenue Avg
Low
High
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-24M$-24M
Low$-24M$-24M
High$-24M$-24M
EPS Avg$-0.58$-0.58
Low$-0.58$-0.58
High$-0.58$-0.58
Analysts (Rev / EPS) / 1 / 1

Earnings Surprises

Recent Analyst Actions

May 26, 2026Evercore ISI
Avalyn Pharma initiated with an Outperform at Evercore ISI
Target:$51.00
+79.5%from $28.41
May 26, 2026Morgan Stanley
Avalyn Pharma initiated with an Overweight at Morgan Stanley
Target:$53.00
+83.8%from $28.84
May 25, 2026Jefferies
Avalyn Pharma initiated with a Buy at Jefferies
Target:$52.00
+80.3%from $28.84
May 25, 2026Guggenheim
Avalyn Pharma initiated with a Buy at Guggenheim
Target:$80.00
+177.4%from $28.84
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.